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Abstract
Background: Nailfold capillaroscopy (NC) is an important tool for the diagnosis of systemic sclerosis (SSc). The
capillaroscopic skin ulcer risk index (CSURI) was suggested to identify patients at risk of developing digital ulcers
(DUs). This study aims to assess the reliability of the CSURI across assessors, the CSURI change during follow-up and
the value of the CSURI in predicting new DUs.
Methods: This multicentre, longitudinal study included SSc patients with a history of DUs. NC images of all eight
fingers were obtained at baseline and follow-up and were separately analysed by two trained assessors.
Results: Sixty-one patients were included (median observation time 1.0 year). In about 40% of patients (assessor 1,
n = 24, 39%; assessor 2, n = 26, 43%) no megacapillary was detected in any of the baseline or follow-up images;
hence the CSURI could not be calculated.
In those 34 patients in whom CSURI scores were available from both assessors (26% male; median age 57 years) the
median baseline CSURI was 5.3 according to assessor 1 (IQR 2.6–16.3), increasing to 5.9 (IQR 1.3–12.0) at follow-up.
According to assessor 2, the CSURI diminished from 6.4 (IQR 2.4–12.5) to 5.0 (IQR 1.7–10.0).
The ability of a CSURI ≥ 2.96 category to predict new DUs was low (for both assessors, positive predictive value
38% and negative predictive value 50%) and the inter-assessor agreements for CSURI categories were fair to
moderate.
Conclusions: In this study, around 40% of patients could not be evaluated with the CSURI due to the absence of
megacapillaries. Clinical decisions based on the CSURI should be made with caution.
Trial registration: Current Controlled Trials, ISRCTN04371709. Registered on 18 March 2011.
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Background
Systemic sclerosis (SSc) is a chronic connective tissue dis-
ease characterised by endothelial cell dysfunction and fibro-
sis of the skin and internal organs [1, 2]. Microangiopathy is
one of the main histopathologic features detectable
early in the course of the disease [3]. A gradual pro-
gression of vascular abnormalities has been observed
during SSc progression [4]. Nailfold capillaroscopy
(NC) is an imaging technique that detects morpho-
logical abnormalities of nailfold microcirculation.
Furthermore, NC is an important tool for the classifica-
tion and diagnosis of SSc in clinical practice [5, 6]. The
three NC patterns early, active and late were found to
be associated with Raynaud’s phenomenon (RP) as well
as with the duration of the disease, possibly reflecting
SSc evolution [4]. Although the diagnostic value of the
NC patterns is well defined [7], different methodologies
have been proposed to assess quantitative NC abnor-
malities in the follow-up of patients with SSc. However,
their clinical applicability remains uncertain.
Sebastiani et al. [8] proposed the capillaroscopic skin
ulcer risk index (CSURI) in 2009, as a quantitative meas-
ure of nailfold capillary damage that predicts the appear-
ance of new digital ulcers (DUs) as well as the
persistence of pre-existing DUs [8, 9]. The CSURI is
based on the number of capillaries in the distal nailfold
capillary row and the number of megacapillaries, as well
as the maximum diameter of the megacapillaries on
capillaroscopic evaluation [8, 9].
In order to gain better insight into the value of moni-
toring quantitative NC abnormalities in clinical practice,
this multicentre study was designed to describe the reli-
ability of the CSURI across different trained assessors, to
describe the change of CSURI during follow-up, to as-
sess the value of the CSURI in predicting new DUs and
to assess associations between the CSURI and demo-
graphic and disease characteristics.
Methods
Study population and design
This multicentre, prospective, observational study was
carried out across eight sites in Switzerland between
2011 and 2015. Adult patients fulfilling the 1980 Ameri-
can College of Rheumatology criteria for SSc and with a
history of DUs were included [10]. DUs were defined as
a painful area with visually discernible depth and a loss
of continuity of epithelial coverage which can be de-
nuded or covered by a scab or necrotic tissue and is vas-
cular in origin. Fissures, paronychia, extrusion of
calcium or ulcers over the metacarpophalangeal joints or
elbows are not regarded as DUs. In order to be included
in this analysis, patients were also required to have at
least one follow-up visit; if a patient had more than one
follow-up visit, the last one was chosen as the follow-up
visit. All inclusion and exclusion criteria are summarised
in Additional file 1: Table S1.
This study was approved by the centres’ ethic commit-
tees and each patient provided written informed
consent.
Demographic patient characteristics and routine clin-
ical data were recorded prospectively on a web-based
electronic data capture system. Table 1 presents a de-
scription of the data collected. Patients underwent NC
at baseline and at follow-up visits. Follow-up visits were
performed if deemed necessary by the centres’ physi-
cians, but were recommended at 3, 6 and 12 months.
Regular external monitoring with primary data verifica-
tion was performed to ensure data quality.
Prior to commencing the study, the study sites’ investi-
gators were trained at an investigator meeting to per-
form NC. The nailfolds of eight fingers (digits 2–5 on
both hands) were examined using the same NC device
equipped with a 200× lens with LED illumination and an
immersion fluid contact adapter (Optilia instruments
AB, Sollentuna, Sweden) in all centres. Four images
Table 1 Description of collected data
Demographics
Age (years)
Sex (female/male)
Smoking habit (never smoker/ex-smoker/current smoker)
Disease characteristics
Time since RP onset (years)
Time since first non-RP manifestation (years)
Cutaneous involvement (limited/diffuse)
Modified Rodnan skin score (range 0–51)
Erectile dysfunction (yes/no; defined as a score below 22 in the
International Index for Erectile Dysfunction-5 [19])
Kidney involvement (yes/no; defined as proteinuria)
History of renal crisis (yes/no)
RP condition score (range 0–10)
DUs (yes/no; defined as a painful area with visually discernible depth
and a loss of continuity of epithelial coverage, which can be denuded
or covered by a scab or necrotic tissue and is vascular in origin; DUs
do not include fissures, paronychia, extrusion of calcium or ulcers
over the metacarpophalangeal joints or elbows.)
Time since first DU (years)
Number of DUs
Major digital vascular complications (none/soft tissue infection/
gangrene/autoamputation)
Laboratory (measured according to local standards in the
respective centres)
Antinuclear autoantibody positivity (yes/no)
Anticentromere autoantibody positivity (yes/no)
Anti-topoisomerase autoantibody positivity (yes/no)
DU digital ulcer, RP Raynaud’s phenomenon
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across the nailfold quadrants of each finger were obtained.
Digital NC images were stored centrally and examined
separately at the end of the study by two identically
trained central assessors (UAW and OD). The central as-
sessors were blinded for the patients, the temporal se-
quence of the fingers and the scoring results of the other
assessor. In each NC image, the assessors assessed the
total number of capillaries in the distal row, the number
of megacapillaries and the maximum diameter of the
megacapillaries. Additionally, the images were also evalu-
ated locally at the centres (local assessors). The qualitative
assessment—that is, the NC pattern (early/active/late)—
was performed by one additional central assessor (RD).
The presence of at least one megacapillary is necessary
to calculate the CSURI [8, 9]. The CSURI is calculated
for only one image per patient per time point; this image
is identified based on the lowest number of capillaries in
the distal row as the first criterion and subsequently the
highest number of megacapillaries as the second criter-
ion [8, 9]. As described in detail elsewhere, the number
of megacapillaries is multiplied by the maximum diam-
eter of the megacapillaries and then divided by the
square of the number of capillaries to form the CSURI
[8, 9]. For part of the analysis, we categorised the CSURI
at 2.96, a threshold which was suggested to be predictive
for the prospective development of DUs [9].
Data analysis
Categorical variables were calculated as frequencies and
percentages, and continuous variables were calculated as
means with standard deviation (SD) or medians with inter-
quartile range (IQR). Chi-square tests/Fisher’s exact tests
and Mann–Whitney U tests were applied for across-group
comparisons. Intraclass correlation coefficients and Cohen’s
κ were calculated to assess the agreement between the two
assessors. Linear regression analysis was applied to evaluate
associations between the change in CSURI between base-
line and follow-up and demographic or disease characteris-
tics. All statistical analyses were performed with Stata/IC
13.1 (StataCorp., College Station, TX, USA).
Results
Between 2011 and 2015, 61 patients from eight centres
were enrolled. The median observation time was 1.0 year
(IQR 1.0–1.1). Of these 61 patients, 24 patients accord-
ing to central assessor 1 (39%) and 26 patients according
to central assessor 2 (43%) had no megacapillaries
present on any assessed finger either at baseline or at
the follow-up visit (Table 2). Due to the absence of
megacapillaries, the CSURI could not be calculated for
those patients. Therefore, for only 34 of the 61 eligible
patients (56%) was the CSURI scorable by both central
assessors at both time points. This percentage of patients
without megacapillaries was similar across all eight cen-
tres (p = 0.72).
According to both central assessors, megacapillaries
were present in 43 patients at baseline (Table 2); 30% of
these showed an early SSc pattern on NC, 44% an active
pattern and 26% a late pattern. Of the 18 patients with-
out megacapillaries present at baseline (Table 2), 6%
(one patient) had an early pattern, 28% a late pattern
and the remaining 66% of patients showed no SSc spe-
cific pattern on NC at baseline.
The following analyses are entirely based on the 34 pa-
tients with an available CSURI by both central assessors
at both time points, named the study population.
The baseline characteristics of the study population
are presented in Table 3. The median observation time
in this population was also 1.0 year (IQR 1.0–1.1). There
were no statistically significant differences between the
patients included in the study population and those ex-
cluded from further analysis. The included patients were,
however, slightly younger (median age 57 years vs
62 years) and nominally more often had diffuse skin in-
volvement (41% vs 33%) than the excluded patients. As
many as 24% of the patients had experienced ulcer com-
plications (soft tissue infections and gangrene).
In the study population, central assessor 1 counted a
median of five capillaries in the distal row (range 2–10)
and a median of one megacapillary (range 1–6) with a
median maximum diameter of 62.5 μm (range 50–130
μm). Central assessor 2 counted a median of five capil-
laries in the distal row (range 2–10) and two megacapil-
laries (range 1–20) with a median diameter of 75 μm
(range 30–180 μm).
The median baseline CSURI scores were 5.3 (IQR 2.6–
16.3) as evaluated by central assessor 1 and 6.4 (IQR
2.4–12.5) as evaluated by central assessor 2. The median
Table 2 Overview of distribution of patients with absent megacapillaries at any of the assessed fingers (i.e. CSURI non-scorability) at
baseline and follow-up according to the central assessors
SSc patients (out of 61 patients) who had no megacapillaries on any of the assessed fingers
Central assessor 1 Central assessor 2 Both central assessors combined
Baseline 15 patients (25%) 17 patients (28%) 18 patients (30%)
Follow-up 15 patients (25%) 18 patients (30%) 18 patients (30%)
Any of the two time points 24 patients (39%) 26 patients (43%) 27 patients (44%)
CSURI capillaroscopic skin ulcer risk index, SSc systemic sclerosis
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baseline CSURI was 8.2 (IQR 4.5–23.6) according to the
local assessors. According to central assessor 1, the me-
dian CSURI score increased to 5.9 (IQR 1.3–12.0) at
follow-up, whereas the median CSURI as evaluated by
central assessor 2 decreased to 5.0 (IQR 1.7–10.0) at
follow-up. The correlation coefficient between the base-
line CSURI of the two assessors was 0.42, indicating a
fair agreement [11]. There was a poor to fair agreement
between the CSURI scored by the central assessors and
the local assessors (central assessor 1/local assessors
0.45; central assessor 2/local assessors 0.38).
As evaluated by central assessor 1, 35% of patients had
a higher CSURI at follow-up compared to 44% when
evaluated by central assessor 2. In only 40% of the 34 pa-
tients was the change in CSURI between baseline and
follow-up in the same direction for both central asses-
sors; that is, an increase as measured by both assessors,
a decrease in the measurements of both assessors or no
change (Fig. 1).
According to both central assessors, 10 patients (29%)
were in the low-risk category (CSURI < 2.96 [9]) at base-
line; however, only seven of those 10 patients were
Table 3 Comparison of baseline demographics and disease characteristics between patients included in this analysis (scorable
CSURI at baseline and follow-up) and those excluded (CSURI not scorable at baseline and follow-up)
Baseline characteristic of study population Included Excluded p value
N 34 27
Age (years) 56.6 (47.8–64.8) 61.7 (53.6–64.6) 0.25
Male sex 26 30 0.79
Smoking habit
Never smoker 47 37 0.23
Ex-smoker 18 37
Current smoker 35 26
Bosentan at any time during the observation period 38 33 0.69
Disease characteristics
Time since RP onset (years) 7.0 (3–15) 5.0 (2–21) 0.65
Time since first non-RP manifestation (years) 4.5 (1–9) 5.0 (2–12) 0.44
Cutaneous involvement
Limited 59 67 0.53
Diffuse 41 33
Erectile dysfunction 13 44 0.29
Kidney involvement 0 4 0.45
History of renal crisis 0 0 –
RP condition score [20] 3.8 (2–7) 5.0 (2–7) 0.49
mRSS 8 (6–13) 9 (4–18) 0.63
Time since first DU (years) 1.5 (0.7–4.2) 2.3 (1.1–5.0) 0.42
DU 76 74 0.83
Number of DUs (in patients with DUs) 3.0 (1–7) 3.5 (1–6) 0.99
Previous major digital vascular complication
None 76 69 0.39
Soft tissue infection 21 15
Gangrene 3 8
Autoamputation 0 8
Laboratory parameters
ANA positive 100 96 0.25
ACA positive 48 45 0.83
Scl-70 positive 34 45 0.46
Data presented as % or median (interquartile range)
ACA anticentromere autoantibodies, ANA anti-nuclear autoantibodies, CSURI capillaroscopic skin ulcer risk index, DU digital ulcer, mRSS modified Rodnan skin
score, RP Raynaud’s phenomenon, Scl-70 anti-topoisomerase I autoantibodies
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concomitantly rated by both assessors as being in the
low-risk category. According to the local assessors, five
patients (15%) were in the low-risk category; however,
only two of those were concomitantly rated by both cen-
tral assessors into the low-risk category. The
inter-assessor agreement of the central assessors for the
baseline CSURI risk category was 0.58, indicating a mod-
erate level of agreement [12]. The inter-assessor agree-
ments of the local assessor and central assessor 1 or 2
were both 0.25, indicating a fair agreement.
Central assessor 1 scored 88% of the patients into the
same risk category at baseline and at follow-up (i.e. ei-
ther low–low risk or high–high risk); the remaining 12%
were in the low-risk category at follow-up, but in the
high-risk category at baseline. According to assessor 2,
73% of patients were in the same risk category at base-
line and follow-up, 21% were in the high-risk category at
baseline and in the low-risk category at follow-up, and
6% were in the low-risk category at baseline and in the
high-risk category at follow-up. The agreement between
the two central assessors of this ‘change in risk categor-
ies’ was fair (κ = 0.37) [12]. There was no agreement be-
tween central assessor 1 and central assessor 2 and the
local assessors regarding this ‘change of risk category’
(κ = – 0.09, κ = – 0.16, respectively).
The prevalence of DU at baseline was 76% (Table 3)
compared to 59% at follow-up. The ability of CSURI ≥
2.96 (i.e. the high-risk category) to predict a higher num-
ber of DUs at follow-up than at baseline visit was rather
low (positive predictive value for both central assessors
38%, for local assessors 48%), as was the ability of CSURI
< 2.96 (i.e. low-risk category) to predict fewer or the
same number of DUs at follow-up compared to baseline
(negative predictive value for both central assessors 50%,
for local assessors 67%). Out of the 34 included patients,
28 patients were classified into the same risk category by
both central assessors. The positive and the negative
predictive values based on these 28 patients were simi-
larly lower (positive predictive value 38%, negative pre-
dictive value 43%) than the predictive values based on all
34 patients. The predictive values in patients who were
treated with bosentan at any time during the observation
period were similar to those who were not treated with
bosentan.
No demographic or disease characteristic was associ-
ated with the change in the CSURI between baseline and
follow-up simultaneously for both CSURIs, the one
scored by assessor 1 and the one scored by assessor 2, in
univariate linear regression (Table 4).
Discussion
This prospective, longitudinal study examined the use of
the CSURI in everyday clinical practice and demon-
strates that 40% of patients in this multicentre study
could not be evaluated with the CSURI at baseline and
follow-up visits, mainly due to a normal NC pattern and
the lack of any megacapillary as a prerequisite for the
calculation of the CSURI [9, 13]. Additionally, the agree-
ment of the CSURI between the two trained and experi-
enced assessors was mediocre at best, as was the
agreement between the two central assessors and the
local assessors.
Our high percentage of non-scorable patients con-
trasts with the first CSURI study and the CSURI valid-
ation study [8, 9]. In the first study all patients had
megacapillaries present, and in the second study only 13
out of an unselected SSc population of 242 patients (5%)
were excluded from the study due to the absence of
megacapillaries [8, 9]. However, in various other studies
that were not applying the CSURI, the percentage of pa-
tients without megacapillaries was comparable to our
high percentage. For instance, in a study of 188 SSc pa-
tients at least one quarter of patients had no megacapil-
laries [14]. Similarly, in two other studies, 24% and 30%
of patients had no megacapillaries in any of the assessed
fingers [15, 16]. Our discrepancies with the first CSURI
studies are difficult to explain with differences of equip-
ment, given the fact that very similar devices were in use
in the first CSURI studies as well as in our study. Our
patient population had similar disease duration as the
patients consecutively recruited into the first CSURI
study [8], but a higher proportion of diffuse SSc patients
(41% vs 9%), which may not explain the lower preva-
lence of megacapillaries in our study.
Fig. 1 Change in CSURI between baseline and follow-up as
evaluated by central assessors 1 and 2. CSURI capillaroscopic skin
ulcer risk index
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In our study, the CSURI had only fair to moderate
inter-rater reliability. This contrasts with an ‘almost per-
fect’ inter-observer reproducibility reported by Sebas-
tiani et al. [8] in the original CSURI study, with κ = 0.96
based on the CSURI, dichotomised at the 2.96 cut-off
value. A slightly lower but still ‘almost perfect’
inter-rater agreement of 0.85 was found in the validation
study [9]. It is unlikely that these discrepancies can be
completely explained with a lack of experience or differ-
ent training, as both central assessors were trained to-
gether by authors of the original CSURI publications
and used the same digital images and imaging software.
The CSURI was created as a prognostic index to pre-
dict the onset of new DUs [8]. In a validation study,
Sebastiani et al. [9] demonstrated high predictive values
for the development of DUs within 3 months, especially
a high negative predictive value of 97%, but also a high
positive predictive value of the CSURI of 81% in patients
with a history of DUs. However, in another study by
Sebastiani et al. [17] a poorer performance of the CSURI
with lower predictive values was also observed in a
population of SSc patients treated with bosentan. Differ-
ences in DU prediction may therefore be explained by
differences in vasoactive medications. When we stratified
our patients by bosentan treatment, we did not observe
major differences in predictive values. It must, however,
also be kept in mind that the predictive values from our
study should not be directly compared with the studies
by Sebastiani et al. as we assessed the predictive values
of a higher number of DUs at follow-up compared to
baseline and not ‘incident DU’ as Sebastiani et al. Add-
itionally, the time between the baseline and the
follow-up visit was considerably longer in our study (me-
dian time 1 year) than in Sebastiani et al.’s studies
(3 months), which could also partly explain the differ-
ences in the predictive power of the CSURI.
A recent systematic literature review critically apprais-
ing studies reporting the prognostic value of NC in SSc
Table 4 Univariate linear regression of ΔCSURI (defined as the difference of CSURI between baseline and follow-up) and
demographics and disease characteristics (n = 34)
Characteristic of study population Central assessor 1 Central assessor 2
β 95% CI p value β 95% CI p value
Age (years) −0.095 −0.75 to 0.56 0.77 0.222 −0.08 to 0.53 0.15
Male sex −0.92 −19.2 to 17.4 0.92 −3.5 −12.2 to 5.3 0.42
Smoking habit
Never smoker Reference Reference
Ex-smoker 3.61 −18.7 to 25.9 0.74 −1.4 − 12.3 to 9.5 0.79
Current smoker 11.54 −6.2 to 29.3 0.20 −3.9 −12.7 to 4.8 0.36
Disease characteristics
Time since RP onset (years) −0.093 −0.75 to 0.56 0.77 0.096 −0.19 to 0.39 0.50
Time since first non-RP manifestation (years) −1.16 −2.9 to 0.6 0.18 0.91 0.1 to 1.7 0.025
Time since first DU (years) −0.81 −3.0 to 1.4 0.46 0.90 0.0 to 1.8 0.046
Previous major digital vascular complication
None Reference Reference
Soft tissue infection −5.62 −25.9 to 14.6 0.58 3.15 −6.4 to 12.7 0.51
Gangrene 5.24 −43.2 to 53.7 0.83 14.74 −8.1 to 37.5 0.20
Cutaneous involvement
Limited Reference Reference
Diffuse 4.05 −12.3 to 20.4 0.62 −3.08 −10.9 to 4.8 0.43
Erectile dysfunction −7.99 −14.2 to −1.8 0.019 −7.28 −21.1 to 6.5 0.25
RP condition score [20] at baseline −0.51 −2.4 to 1.4 0.59 −0.11 −1.0 to 0.8 0.81
mRSS at baseline −0.04 −0.9 to 0.9 0.93 − 0.002 −0.4 to 0.4 0.99
Number of DUs at baseline 1.05 −0.8 to 2.9 0.25 0.55 −0.3 to 1.4 0.21
Laboratory parameters
ACA positive 6.08 −10.4 to 22.5 0.46 −0.02 −8.1 to 8.0 0.99
Scl-70 positive −16.5 −34.8 to 1.8 0.075 −2.73 −12.1 to 6.7 0.56
ACA anticentromere autoantibodies, CI confidence interval, CSURI capillaroscopic skin ulcer risk index, DU digital ulcer, mRSS modified Rodnan skin score, RP
Raynaud’s phenomenon, Scl-70 anti-topoisomerase autoantibodies
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also assessed the predictive value of the CSURI [18]. In
line with our study, Paxton and Pauling [18] conclude
that it is difficult to draw robust conclusions regarding
the prognostic role of the CSURI; the reason for this be-
ing high levels of potential biases relating to study con-
founding as well as the statistical analyses.
It needs to be mentioned that our study has a rather
limited sample size, which restricts the power to assess
CSURI predictors in terms of demographic and disease
characteristics. However, the mediocre performance of
the CSURI regarding the inter-rater differences, as well
as the high number of patients who could not be in-
cluded due to the absence of megacapillaries, will not be
a result of chance alone, even if a larger sample size
would naturally have been beneficial.
Conclusions
The CSURI was not applicable in a large percentage of
patients due to the absence of megacapillaries and dem-
onstrated only fair to moderate inter-rater reliability.
Thus, in routine clinical practice, the CSURI should be
used with caution for treatment decisions and prediction
of incident DUs.
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